Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

Recent Questions

Zemdri plazomicin gain exclusivity 2028 patent 2031?
When will latisse patent expire?
When is the expected fda decision date for apotex's ruxolitinib resubmission?
Albendazole side effects in humans?
When does guselkumab patent expire?

What was the initial cancer indication for keytruda?

See the DrugPatentWatch profile for keytruda

Keytruda's Original FDA Approval

Keytruda (pembrolizumab) received its first U.S. FDA approval on September 4, 2014, for unresectable or metastatic melanoma in patients whose tumors express PD-L1, as determined by an FDA-approved test.[1][2]

How the Approval Happened

The approval stemmed from the KEYNOTE-001 trial, a phase 1 study showing 33% objective response rate and 4-month median duration in PD-L1-positive advanced melanoma patients.[1][3] This marked the first PD-1 inhibitor approval, based on accelerated pathways for breakthrough therapies.

Expansion to Other Cancers

Keytruda quickly gained approvals beyond melanoma:
- December 2014: Ipilimumab-refractory melanoma.
- October 2015: Non-small cell lung cancer (NSCLC) expressing PD-L1.
By 2024, it has 40+ indications across 18 tumor types, including MSI-H cancers regardless of location.[1][4]

Why Melanoma First?

Melanoma's high unmet need and PD-1 pathway's role in immune evasion made it the lead; early trials prioritized immunotherapy-resistant cases.[3][5]

Current Status and Patents

Keytruda remains Merck's top seller at $25B+ annual revenue. U.S. composition-of-matter patent expires in 2028, with challenges ongoing; pediatric exclusivity adds six months.[6][1]

[1]: FDA Approval History
[2]: Keytruda Prescribing Information
[3]: NEJM KEYNOTE-001 Results
[4]: Merck Keytruda Indications
[5]: ASCO Post on PD-1 History
[6]: DrugPatentWatch.com - Keytruda Patents



Other Questions About Keytruda :

keytruda primary u.s. patent expiration Can keytruda assistance cover all treatment costs? Will keytruda be approved for new uses? Can you tell me the year keytruda gained fda approval for cancer care? What are the advantages of keytruda over other cancer treatments? Are there any patient assistance programs for keytruda's cost? Keytruda patent expiry us?

AI-Drug Label Prescribing Information Alignment Report

98
98%
Grade A

Excellent

Mostly Aligned

Patient Risk: Low

Summary

The evaluated claim matches the FDA-approved melanoma indications in Prescribing Information Section 1.1 (unresectable/metastatic melanoma and adjuvant treatment for Stage IIB/IIC/III after complete resection in adults and pediatric patients ≥12 years).

Category Scores

Indication
100
Excellent

Accurate Statements

KEYTRUDA is indicated for unresectable or metastatic melanoma; and for adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.
Prescribing Information Section 1.1 (Melanoma): indicated for treatment of patients with unresectable or metastatic melanoma; and for adjuvant treatment of adult and pediatric (12 years and older) patients with Stage IIB, IIC, or III melanoma following complete resection.

Unsupported Statements

Contradictions

Important Omissions

Safety Assessment

Potential Patient Risk: Low
Only indication statements were evaluated; no dosing, safety, or risk-related claims were assessed.

Regulatory Assessment

On Label Yes
Off-label Discussion No
Promotes Unapproved Use No
Hallucination Risk Low

Recommendation

Mostly Aligned

Primary Issue

Suggested Improvement

Drug Brand Mention Assessment

Branding Score
71
Visibility
65
Mentioned
Ranking
#1
Sentiment
60
Recommendation Status
mentioned only
Brand Perception
Best Known For

first U.S. FDA approval ... for unresectable or metastatic melanoma ... whose tumors express PD-L1

Core Claims
  • Keytruda received its first U.S. FDA approval on September 4, 2014
  • Approval was for unresectable or metastatic melanoma with tumors expressing PD-L1
  • The approval stemmed from the KEYNOTE-001 trial
Differentiators
  • First approval was based on PD-L1 expression as determined by an FDA-approved test
  • Approval described as the first PD-1 inhibitor approval
Pricing Perception: Not Mentioned